Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSP191 in Matched Unrelated Donor Transplantation for CGD
NCT05600907Phase 1Active, not recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2023
- Primary completion
- Nov 2036
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of briquilimab in chronic granulomatous disease (CGD), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Early and long term engraftment at 2 years. Started Jan 2023; status: active, not recruiting.
02
Drugs
briquilimab
03
Conditions
chronic granulomatous disease (CGD)
Beyond the preview
Go deeper on NCT05600907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05600907.